EQS Voting Rights Announcement: Dermapharm Holding SE Dermapharm Holding SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution 31.05.2023 / 14:45 CET/CEST Dissemination of a Voting Rights Announcement transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notification of Major Holdings 1. Details of issuer Name: | Dermapharm Holding SE | Street: | Lil-Dagover-Ring 7 | Postal code: | 82031 | City: | Grünwald Germany | Legal Entity Identifier (LEI): | 5299009F0KNZINQQQK37 | 2. Reason for notification X | Acquisition/disposal of shares with voting rights | | Acquisition/disposal of instruments | | Change of breakdown of voting rights | | Other reason: | 3. Details of person subject to the notification obligation Legal entity: Mawer Investment Management Ltd City of registered office, country: Calgary, Canada | 4. Names of shareholder(s) holding directly 3% or more voting rights, if different from 3. 5. Date on which threshold was crossed or reached:6. Total positions | % of voting rights attached to shares (total of 7.a.) | % of voting rights through instruments (total of 7.b.1 + 7.b.2) | Total of both in % (7.a. + 7.b.) | Total number of voting rights pursuant to Sec. 41 WpHG | New | 3.004093610698 % | 0.00 % | 3.004093610698 % | 53840000 | Previous notification | n/a % | n/a % | n/a % | / | 7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG) ISIN | Absolute | In % | | Direct (Sec. 33 WpHG) | Indirect (Sec. 34 WpHG) | Direct (Sec. 33 WpHG) | Indirect (Sec. 34 WpHG) | DE000A2GS5D8 | 0 | 1617404 | 0.00 % | 3.00 % | Total | 1617404 | 3.004093610698 % | b.1. Instruments according to Sec. 38 (1) no. 1 WpHG Type of instrument | Expiration or maturity date | Exercise or conversion period | Voting rights absolute | Voting rights in % | | | | 0 | 0.00 % | | | Total | 0 | 0.00 % | b.2. Instruments according to Sec. 38 (1) no. 2 WpHG Type of instrument | Expiration or maturity date | Exercise or conversion period | Cash or physical settlement | Voting rights absolute | Voting rights in % | | | | | 0 | 0.00 % | | | | Total | 0 | 0.00 % | 8. Information in relation to the person subject to the notification obligation X | Person subject to the notification obligation is not controlled nor does it control any other undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.). | | Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity: | Name | % of voting rights (if at least 3% or more) | % of voting rights through instruments (if at least 5% or more) | Total of both (if at least 5% or more) | 9. In case of proxy voting according to Sec. 34 para. 3 WpHG (only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG) Date of general meeting: Holding total positions after general meeting (6.) after annual general meeting: Proportion of voting rights | Proportion of instruments | Total of both | % | % | % | 10. Other explanatory remarks: Date 31.05.2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com |
Language: | English |
Company: | Dermapharm Holding SE |
| Lil-Dagover-Ring 7 |
| 82031 Grünwald |
| Germany |
Internet: | ir.dermapharm.de |
|
End of News | EQS News Service |
1646179 31.05.2023 CET/CEST